medullaoblongata78
232 posts













$PALI Piper Lastly,doc said he is excited for $PALI-2108's IBD program to kick off&progress towards later-stage data, where PALI plans to initiate a Ph2 UC trial in ~3Q26 (2H26). Ultimately, the doc believes there is strong evidence to support PALI-2108's competitive product profile in UC where he thinks a placebo-adjusted ~20% clinical remission rate at 12-weeks would be viewed as a win. Moreover,will be looking at overall safety/tolerability to understand PALI-2108's potential positioning within UC, where we think PALI-2108 is instilled with potential to become an effective and safe/tolerable oral therapeutic option. I N D U S T R Y A p r i l 1 3 , N O T E 2 0 2 6 Topic #1: Overview of doc's practice Our doc's clinic has ~2K IBD patients where ~half are on advanced therapies (biologic or small molecule











